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This viewpoint summarizes a selection of
nanotechnology-based key concepts relevant to
critical care medicine. It focuses on novel approaches
for a trigger-dependent release of antimicrobial
substances from degradable nano-sized carriers,
the ultra-sensitive detection of analytes in body fluid
samples by plasmonic and fluorescent nanoparticles,
and the rapid removal of pathogens from whole
blood using magnetic nanoparticles. The concepts
presented here could significantly contribute to the
prevention, diagnosis and therapy of bacterial infections
in future and it is now our turn to bring them from the
bench to the bedside.mechanical, electrical, magnetic, optical and chemical
properties change when compared to macroscopic systems.Sepsis is a devastating medical condition, particularly in
times when antibiotic resistance rates are rising. Despite
increasing insight into the complex pathophysiology of
sepsis, one of the major disappointments during the past
30 years has been the failure to convert advances in our
understanding into effective new therapies [1]. Both highly
specific agents and drugs with pleiotropic effects have
been investigated, but with limited success. Faced with
such disappointing results, the current approach to the
development of sepsis therapies has been challenged by
many. Translation of preclinical success stories into clinics
is extremely challenging and disconnects basic sepsis
research from the clinic [2]. Sepsis is not only incredibly
difficult to treat, it is also hard to diagnose. Particularly in
the critically ill, it is often difficult to differentiate patients
urgently needing antibiotic treatment from those suffering
from non-infectious systemic inflammation due to other* Correspondence: inge.herrmann@empa.ch
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unless otherwise stated.conditions, where antibiotic treatment leads to unwanted
side effects, such as Clostridium difficile diarrhea or other
complications. Diagnostic uncertainty leads to overuse
of antibiotics in hospitals and out-patient settings, and
ultimately contributes to the rising rates of antimicrobial
resistance, a major global healthcare challenge. Advances
in intensive care along with increased awareness have
helped to reduce the risk of imminent death associated
with sepsis over recent decades; however, novel approaches
to prevent, diagnose and treat sepsis remain major clinical
needs that may only be adequately addressed by employing
novel technologies.
The advent of nanotechnology has brought with it
an astonishing number of novel tools enabling novel
technological solutions. As the size of a system decreases,
While bulk gold is shiny, golden in color, inert, and
conducts electricity, nano-sized gold particles with a
diameter of 10 nm are red in color, catalytically active
and semi-conductive [3]. Similarly, opaque materials
may become transparent (bulk copper versus copper
nanoparticles), stable materials may become combustible
(bulk iron versus iron nanoparticles) and insoluble
materials may become soluble (bulk silver versus silver
nanoparticles). With the increase in surface-to-volume
ratio, chemically inert materials may become catalytically
active. Such dramatic changes in properties give access to
a whole new world of material properties. By engineering
systems at the (sub-)nanoscale, we can make use of
these altered material properties and gain the ability
to construct high performance systems from the bottom
up. Changing the properties of materials opens up a multi-
tude of new opportunities to improve state-of-the-art
technologies; we can make systems stronger, more durable,
more sensitive, multifunctional, and so on.
Here, I discuss recent developments in the field of nano-
scale engineering that could potentially be employed tois is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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focus on a few landmark concepts that could potentially
be useful in the prevention, detection and treatment of
bacterial infection and sepsis.
Generally, the best way to eliminate a problem is to
eliminate its cause. Implantable devices and endotracheal
tubes are a major source of hospital-acquired infec-
tion responsible for more than 40 % of all episodes of
nosocomial sepsis. Silver-based compounds have been
exploited for their medicinal properties for centuries;
however, due to the emergence of antibiotics, the use
of silver-based compounds has lost importance [4]. With
the emergence of antimicrobial resistance, metallic silver
in the form of silver nanoparticles has made a remarkable
comeback as a potential antimicrobial agent. In contrast
to older silver-containing formulations that were rapidly
inactivated by the environment, nano-sized silver particles
ensure a sustained release of silver ions providing
antimicrobial activity [5]. However, the toxicity of silver
nanoparticles remains a concern. While some studies have
observed cytotoxic effects of silver nanoparticles in vitro,
systemic toxicity of ingested silver nanoparticles is rarely
seen. Supporting this, Wong and Liu [6] did not
observe any overt systemic effects when injecting silver
nanoparticles into mice intravenously despite the relatively
high dose. Oral administration of silver nanoparticles
of up to 32 ppm to healthy volunteers did not induce
observable clinically important toxicity markers [7].
However, the overall significance in the in vivo setting
and the applicability to humans remain largely unknown
[6]. Remarkably, a trigger-dependent release of silver ions
has been achieved by using silver nanoparticle-decorated
biodegradable tricalcium phosphate particles (Fig. 1).
Bacteria, when present, degrade the tricalcium phosphate
matrix, thereby releasing silver that then in turn kills
them. If no bacteria are present, no silver is released,
hence potentially minimizing side effects when applied in
clinical settings [8]. As such trigger-dependent systems
greatly reduce the required dose of silver nanoparticles,
they may be seen as a first step towards the safe use of
silver nanoparticle-coated surfaces in clinics. Such
self-sterilizing systems may significantly improve the
performance of currently used silver-based coatings
(for example, on surfaces and textiles), and once safety con-
cerns have been ruled out also on catheters, endotracheal
tubes, or implants [9]. Trigger-dependent silver-based
antimicrobial coatings may thus become an integral part of
controlling bacterial spread in hospital environments.
Early diagnosis is vital to ensure that early treatment is
started and has a direct impact on patient outcome.
Sepsis is a medical emergency and immediate treatment
is required, necessitating quick, early and accurate diagno-
sis. However, sepsis is difficult to diagnose based solely
on clinical symptoms. Blood cultures often require longincubation times, with many of them coming back as
false negatives. While over 170 biomarkers have been
investigated, few have entered clinical routine [10]. A
singular ideal biomarker has not yet been identified
and recent research efforts have focused on determining
the diagnostic relevance of multiple biomarkers when
used in concert [10, 11]. However, such analyses are cost-
intensive and laborious as subtle changes in biomarker
concentrations need to be detected within a few minutes,
preferably in a point-of-care compatible setting, posing a
major challenge to currently used routine measurements
such as enzyme-linked immunoassays or polymerase chain
reaction systems. Nanoparticle-based biosensors have the
potential to improve or supersede current analytics
[12]. By employing colloidal fluorescent or plasmonic
nanoparticles, detection systems can be made more
sensitive, reaching levels of naked-eye detection of
single analytes (Fig. 1) [12]. For example, plasmonic
sensors based on gold nanoparticle growth in the presence
of hydrogen peroxide generated by an enzymatic reaction
were employed to detect single molecules in serum by the
naked eye [13, 14]. Similarly, Chapman and colleagues
[15] reported on a point-of-care compatible lateral flow
device enabling naked-eye detection of one nanomolar
concentrations of human phospholipase in serum within
10 minutes. This assay is based on the enzyme-triggered
release of multi-armed polymers from a liposome
substrate that then aggregate small gold nanoparticles.
The adhesion of gold nanoparticle networks to the lateral
flow device then leads to the appearance of a red test line
due to the localized surface plasmon resonance effect of
the gold. If no enzyme (and thus no linker) is present, the
gold nanoparticles flow past the test line without adhering,
and thus no line is visible. Such nanoparticle-based
systems enable us to detect analytes in body fluid samples
at ultra-low concentrations by the naked eye in just a few
minutes. Importantly, the size-dependent properties of
nanoparticles (for example, gold, quantum dots) also
facilitate the simultaneous detection of multiple analytes
in the same system [12]. By choosing orthogonal signal
generation and detection methods, a whole panel of
analytes (for example, different enzymes, antigens, or
nucleic acids) can be detected in a single sample at the
same time [16, 17]. Such assays have the potential to
decrease the time-to-result and increase sensitivity, which
together with the clinical picture would allow doctors to
make early clinical management decisions more confi-
dently. Furthermore, such systems could eventually allow
rapid analysis of biomarker panels at the patient’s bedside,
and potentially even in resource-limited environments.
When sepsis has been diagnosed, antibiotic therapies
need to be initiated. However, the treatment of sepsis
patients is extremely complex and effectiveness of the
antibiotic therapy heavily relies on the rapid and reliable
Fig. 1 Examples of nanotechnology-based solutions that could help to prevent, detect or treat bacterial infections. Trigger-dependent release of
silver ions from silver nanoparticles could help to prevent bacterial spread on surfaces of implants, cathethers or external surfaces and textiles in
hospitals (top left). Aggregation of gold nanoparticles induced by the presence of an analyte changes the color of emission in a way that is visible
to the naked eye, thus providing an attractive way to rapidly detect (single) biomolecules in a point-of-care compatible setting (top right). Drug
molecules, such as antibiotics, can be encapsulated in enzyme-cleavable capsules. This allows the trigger-dependent and sustainable use of antibiotics
(bottom left). Pathogens can be removed from whole blood by magnetic blood purification. Tiny magnetic particles capture the pathogens
(for example, bacteria) and can then be separated from the blood by an external magnetic field (bottom right)
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diagnostic uncertainty, the pharmacokinetics of the
administered antibiotics are usually altered, especially in
patients with pulmonary infections, thus necessitating
prolonged administration of excessive dosages, which
often leads to the development of adverse side effects
and antimicrobial resistance [18]. Recent studies have
shown that the encapsulation of antimicrobial agents
within nano-sized capsules (for example, liposomes,
polymerosomes) improves pharmacokinetics and tissue
distribution, target selectivity, (intracellular) delivery and
overall antimicrobial effects while reducing side effects
[18–20]. The properties of capsules (size, charge, fluidity)
can be tailored in order to target extracellular or intracellu-
lar targets. Intracellular pathogens, such as mycobacteria,
have been shown to be eradicated by using conventionalliposomes that are taken up by phagocytes. Capsules with
stealth properties can be designed to increase blood
circulation time, achieve sustained drug release and
introduce target specificity. Target specificity of liposomal
formulations may be achieved either by using (positively)
charged liposomes that adhere to (negatively charged)
pathogens or biofilms (for example, in the lung), or by
introducing specific targeting moieties, such as proteins,
antibodies or oligosaccharides on the liposome surface
[20]. Moreover, it has been demonstrated that antibiotics
can be released in a trigger-dependent manner by
using pH- or thermoresponsive capsosomes or enzyme-
cleavable hyaluronic acid-based capsules [20, 21]. The
hyaluronic-based capsules are cleavable by hyaluronidase
secreted by bacteria, such as Staphylococcus aureus and
Escherichia coli, thereby ensuring that the antibiotics are
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antibiotics-independent approach, engineered liposomes
have been employed as decoy targets to sequester bacterial
toxins [22]. This significantly increased survival in a
murine model of bacterial septicemia. The first clinical
evaluations of this technique conducted on patients suffer-
ing from severe streptococcal pneumonia are scheduled
for this year.
As it is not always possible to identify the causative
microorganism in time, however, it is highly desirable to
have treatment options that work without the need to
first identify the source of infection and the causative
microbe. It has recently been shown that magnetic blood
purification enables rapid removal of disease-causing
factors from whole blood [23–25]. In magnetic blood
purification, tiny magnetic particles functionalized with
capturing ligands are injected into whole blood where
they bind to target compounds (Fig. 1). By applying an
external magnetic gradient field, the pathogen-loaded
magnetic particles can then be separated from the
blood. The process can be carried out in an extracorporeal
setting (similar to hemodialysis) where cleansed (pathogen-
free blood) would be recirculated into the body. A
multitude of compounds have been successfully removed
from blood in vitro and in vivo (rat model) in recent years,
including heavy metal ions [23, 26–28], small molecule
drugs [23, 25], proteins (for example, cytokines) [23],
endotoxins [24, 25] and bacteria [24, 25, 29]. Interestingly,
by using mannose-binding lectin, Kang and colleagues
[25] demonstrated >90 % removal of bacteria from blood
without the need for identification of the bacteria
prior to treatment in a rodent model. This approach
could effectively bridge the gap until the causative
microbes have been identified (for example, by blood
culture or by analyzing the pathogens bound to the
magnetic beads) and optimal antibiotic therapy can be
initiated. The group is currently testing the biospleen
device in a pig model and it is expected that the system
will enter clinical evaluation in a couple of years.
As for every new technology, safety evaluations are
a pivotal and most often rate-determining step in the
translational process. Toxicity, hemocompatibility, off-target
effects as well as long-term effects of nanomaterials need to
be evaluated case by case (and under relevant conditions)
before a nanotechnology-enabled therapy can be considered
safe. Classical toxicology protocols may not always be
suitable for the assessment of nanomaterials as their
interaction with biological systems is governed by a series
of characteristics not found for molecules: chemically
reactive interfaces, the combination of solid-state pro-
perties and mobility, and altered biodistribution (more
details can be found in [30]). In order to minimize
adverse side-effects, therapeutic applications should
focus on biodegradable nanomaterials consisting ofnon-toxic elements. Ultimately, successful translation
of nanotechnology-enabled concepts heavily relies on the
close collaboration between scientists and clinicians in
interdisciplinary teams. Taken together, nanotechnology-
based approaches offer a multitude of opportunities and
immense potential for improved detection and treatment
of bacterial infections and beyond. It is now our turn to
take these technologies and bring them from the lab to
the bedside by making safe use of them.
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